You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The deal aims to create novel products to help diagnostic companies manage risks of interferences in current test designs.
The deal gives DiaSorin the exclusive rights to TTP's sample-to-answer diagnostic system for human in vitro diagnostic applications.
The PAVmed subsidiary will have the option to license the biomarkers for a year after the completion of a Phase II study evaluating their accuracy.
Since 2017, the companies have been jointly developing an in vitro assay for measurement of sTREM-1 in plasma samples of septic shock patients.
As part of the expanded deal, Oncore will offer StageZero's BreastSentry and Prostate Health Index tests, as well as ColonSentry.
While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.
Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform.
The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
Under the new 15-year exclusive agreement, the test will become available through all of Sonic's clinical labs and anatomic pathology practices in the US.
Siemens Healthineers will use the technology, which Quanterix acquired as part of its buy of UmanDiagnostics, to develop blood-based Nf-L clinical tests.